Journal article
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
A Iravani, MM Osman, AM Weppler, R Wallace, A Galligan, A Lasocki, MO Hunter, T Akhurst, MS Hofman, PKH Lau, D Kee, G Au-Yeung, S Sandhu, RJ Hicks
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2020
Abstract
Purpose: We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) following first-line combination-immune checkpoint inhibitor (combination-ICI) therapy for advanced melanoma. Methods: We retrospectively reviewed outcomes in patients who had (1) first-line nivolumab plus ipilimumab; (2) pre- and post-treatment FDG-PET/CT scans (pre-FDG-PET/CT and post-FDG-PET/CT) within 2 and 4 months of starting ICI, respectively; and (3) at least one lesion assessable by PET response criteria in solid tumors (PERCIST). Extracranial response was monitored by 3 monthly FDG-PET/CT. Whole-body metabolic tumor volume (wbMTV) was measured pre- and post-tr..
View full abstractGrants
Awarded by Victorian Cancer Agency
Funding Acknowledgements
This research was partially supported by the Victorian Cancer Agency.